301103.SHE Liaoning He Eye Hospital Group Co. LTD.
- Market cap
- CNY 2.43B
- P/E
- 85.6x
- P/B
- 1.26x
- ROE
- 3.7%
- Dividend yield
- 0.96%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301103.SHE undervalued?
Graham number301103.SHE trades 119.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Liaoning He Eye Hospital Group Co. LTD. fundamental analysis
No fundamental analysis for Liaoning He Eye Hospital Group Co. LTD. yet.
Liaoning He Eye Hospital Group Co. LTD. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Liaoning He Eye Hospital Group Co. LTD.
Liaoning He Eye Hospital Group Co., LTD., together with its subsidiaries, provides ophthalmological and optometry services to patients with eye diseases in China. The company offers treatment for common blinding eye diseases, including cataracts, glaucoma, and vitreoretinal disorders; specialized treatments, such as dry eye and traditional Chinese medicine; and optometry services, including optical correction, refractive surgery, and vision training for refractive errors. It…
Full company profileLiaoning He Eye Hospital Group Co. LTD. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Liaoning He Eye Hospital Group Co. LTD. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 746M | 838M | 962M | 955M | 1.19B | 1.10B | 1.09B | 1.18B |
| Gross Profit | 322M | 364M | 388M | 367M | 495M | 423M | 448M | 500M |
| Operating Income | 107M | 142M | 136M | 63.6M | 88.3M | -1.11M | 50.4M | 97.7M |
| EBITDA | 171M | 187M | 259M | 189M | 230M | 125M | 168M | 112M |
| Net Income | 80.6M | 100M | 86.4M | 32.6M | 63.6M | -27.4M | 27.3M | 71.9M |
| EPS | 0.68 | 0.85 | 0.73 | 0.21 | 0.40 | -0.17 | 0.17 | 0.45 |
| Balance Sheet | ||||||||
| Total Assets | 989M | 1.35B | 1.42B | 2.61B | 2.48B | 2.23B | 2.18B | 2.25B |
| Total Liabilities | 128M | 388M | 371M | 430M | 411M | 346M | 297M | 322M |
| Shareholders' Equity | 862M | 963M | 1.05B | 2.17B | 2.08B | 1.88B | 1.88B | 1.93B |
| Cash & Short-term Investments | 543M | 613M | 699M | 1.64B | 1.59B | 767M | 542M | 388M |
| Cash Flow | ||||||||
| Operating Cash Flow | 120M | 170M | 214M | 148M | 177M | 156M | 157M | - |
| Capital Expenditure | 111M | 93.2M | 71.2M | 49.1M | 189M | 116M | 33.7M | 27.2M |
| Free Cash Flow | 8.94M | 76.6M | 142M | 98.9M | -11.7M | 39.3M | 123M | 207M |
| Ratios | ||||||||
| ROE | 9.4% | 10.4% | 8.2% | 1.5% | 3.1% | -1.5% | 1.5% | 3.7% |
| ROA | 8.1% | 7.4% | 6.1% | 1.3% | 2.6% | -1.2% | 1.3% | 3.2% |
| Net Profit Margin | 10.8% | 12.0% | 9.0% | 3.4% | 5.4% | -2.5% | 2.5% | 6.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Liaoning He Eye Hospital Group Co. LTD. dividends
- Dividend yield
- 0.96%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 85.2%
- Ex-dividend date
- May 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 23.3M | 0.15 | 85.2% |
| 2024 | CNY 94.0M | 0.59 | - |
| 2023 | CNY 158M | 1.00 | 248.7% |
| 2022 | CNY 72.9M | 0.46 | 223.8% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jun 1, 2022.
Who owns Liaoning He Eye Hospital Group Co. LTD.
- Insiders 53.67%
- Institutions 9.14%
- Public & others 37.19%
- Shares outstanding 158M
- Free float 63.7M
Liaoning He Eye Hospital Group Co. LTD. company profile
- Company name
- Liaoning He Eye Hospital Group Co. LTD.
- Ticker
- 301103.SHE
- ISIN
- CNE100005899
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 3,174
- Fiscal year end
- December
- Address
- Jiataihe International Building, Shenyang, China, 110034
- Phone
- 86 40 0909 0400
- Website
- hsyk.com.cn
About Liaoning He Eye Hospital Group Co. LTD.
Liaoning He Eye Hospital Group Co., LTD., together with its subsidiaries, provides ophthalmological and optometry services to patients with eye diseases in China. The company offers treatment for common blinding eye diseases, including cataracts, glaucoma, and vitreoretinal disorders; specialized treatments, such as dry eye and traditional Chinese medicine; and optometry services, including optical correction, refractive surgery, and vision training for refractive errors. It also provides vitreoretinal diagnosis and treatment services, non-surgical and cataract treatment, and other eye disease diagnosis and treatment services; and cataract surgery, refractive error correction surgery, vitreoretinal surgery, and other surgical procedures. In addition, the company offers refractive cataracts, LASIK surgery, myopia prevention, medical fitting, diabetic retinopathy, dry eyes and cornea, gene diagnosis, and comprehensive eye disease solutions. Further, it engages in the sale and testing of medical devices; wholesale of optometry products; business and technical services; technology development, consulting, promotion, and application; import and export trade; wholesale business; and health and social work activities. Liaoning He Eye Hospital Group Co., LTD. was founded in 1995 and is based in Shenyang, China.
Liaoning He Eye Hospital Group Co. LTD. management
5- Mr. Wei HeChairman of the Board & Acting Board Secretary · born 1960
- Mr. Yuehua HeCFO & Financial Director · born 1978
- Ms. Ling XuDeputy General Manager · born 1977
- Mr. Chun Hui ZhengDeputy General Manager · born 1978
- Yanming WangAccounting Supervisor